Section Arrow
Quote
TVGN.NASDAQ
- Tevogen Bio Holdings Inc.
Quotes are at least 15-min delayed:2026/04/13 10:27 EDT
Regular Hours
Last
 5.9065
+0.1765 (+3.08%)
Day High 
5.9065 
Prev. Close
5.73 
1-M High
7.65 
Volume 
638 
Bid
5.44
Ask
6
Day Low
5.59 
Open
5.59 
1-M Low
4.1353 
Market Cap 
23.86M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.95 
20-SMA 5.11 
50-SMA 9.46 
52-W High 75.5 
52-W Low 4.1353 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.08/-13.00
Enterprise Value
29.38M
Balance Sheet
Book Value Per Share
-4.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
VRAXVirax Biolabs Group Limited0.16711+0.06301+60.53%-- 
ALLOAllogene Therapeutics3.99+1.27+46.69%-- 
REPLReplimune Group1.525-3.235-67.96%-- 
RVMDRevolution Medicines130.735+34.305+35.58%-- 
IDYAIDEAYA Biosciences36.615+6.115+20.05%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.